Delivering on the promise of mRNA cancer vaccines in the immuno-oncology clinical setting

The recent unveiling of highly promising data from the Keytruda in combination with V940 (mRNA-4157) development program has breathed new life into the cancer vaccine field. David McCall, Senior Editor, Nucleic Acid Insights, talks to Dr Jane Healy, Vice President of Early Oncology Development, Merck Research Laboratories, about this ongoing study and Merck’s future plans to explore the full potential of mRNA technology in the oncology space.

Please enter your email to access content Read now